Search Results

The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.

MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease in collaboration with the Biomarkers of Aging Consortium announced the launch of the next phase of the Biomarkers of Aging Challenge Series.

Sirona Biochem Corp. is pleased to announce that its innovative anti-aging ingredient, GlycoProteMim™, has been featured in Stonegate Healthcare’s newly published research report, “Novel Treatments for Age-Related Skin Problems.” The report provides an in-depth analysis of the latest advancements in the $12.5 billion anti-aging skincare market.

Researchers at the newly-formed Optimal Aging Institute at NYU Langone Health have been awarded $31 million by the National Institutes of Health for a diverse, ten university cohort to study how vascular risk factors contribute to dementia and other age-related disorders in those over the age of 85, building upon existing research.

Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate - technology, announced the appointment of Ulf Grawunder, Ph.D. to its scientific advisory board.

Researchers from Children’s Hospital of Philadelphia found that young children between the ages of 5 and 12 were more likely to experience a concussion from recreation and other non-sport activities, yet those injuries were not seen by specialists until days later compared with sports-related concussions in the same age group.

The Berlin Heals Holding AG has developed the C-MIC device, a revolutionary and life-saving treatment for patients with heart failure.

GSK plc announced that the US Food and Drug Administration has approved AREXVY Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease in adults 50 through 59 years of age who are at increased risk.